Are you over 18 and want to see adult content?
More Annotations
A complete backup of kuenstlerhaus-lukas.de
Are you over 18 and want to see adult content?
A complete backup of mundonomadesdigitais.com.br
Are you over 18 and want to see adult content?
A complete backup of ericmelic.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of inspiranzadesigns.com
Are you over 18 and want to see adult content?
A complete backup of fifa-analytics.com
Are you over 18 and want to see adult content?
A complete backup of toolsdirectsales.com
Are you over 18 and want to see adult content?
A complete backup of creditmantri.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of oakvillerealestate.com
Are you over 18 and want to see adult content?
A complete backup of levyrestaurants.com
Are you over 18 and want to see adult content?
A complete backup of cbdoilofhemp.com
Are you over 18 and want to see adult content?
A complete backup of schwarzwaelder-bote.de
Are you over 18 and want to see adult content?
A complete backup of maxbrookszombieworld.com
Are you over 18 and want to see adult content?
A complete backup of onlinecasinoflow.com
Are you over 18 and want to see adult content?
Text
Science companies
HOME
Focus. Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology. Strong entrepreneurial teams with deep domain knowledge. Disruptive, innovative tech addressing highly unmet medical needs and attractive markets. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in PROFILE - WELLINGTON PARTNERS Venture Capital for life science. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. PROFILE - WELLINGTON PARTNERS Biography. Karl joined Wellington as Managing Partner in January 2020. He brings to Wellington a strong track record of investments in early and later stage life science companies as well as deep sector knowledge and an extensive global network from over 20 years of industry experience. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Venture Capital for life science. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. PROFILE - WELLINGTON PARTNERS Biography. Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody. WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Wellington Partners invests Venture Capital in Technology and LifeScience companies
HOME
Focus. Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology. Strong entrepreneurial teams with deep domain knowledge. Disruptive, innovative tech addressing highly unmet medical needs and attractive markets. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in PROFILE - WELLINGTON PARTNERS Venture Capital for life science. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. PROFILE - WELLINGTON PARTNERS Biography. Karl joined Wellington as Managing Partner in January 2020. He brings to Wellington a strong track record of investments in early and later stage life science companies as well as deep sector knowledge and an extensive global network from over 20 years of industry experience. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Venture Capital for life science. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. PROFILE - WELLINGTON PARTNERS Biography. Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody.HOME
Focus. Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology. Strong entrepreneurial teams with deep domain knowledge. Disruptive, innovative tech addressing highly unmet medical needs and attractive markets. PORTFOLIO - WELLINGTON PARTNERS Adrenomed. Adrenomed develops a first-in-class monoclonal antibody (Adrecizumab) that targets the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock. PORTFOLIO - WELLINGTON PARTNERS Adconion Media Group (AMG) AMG’s US was sold to Amobee Inc. for $235 million in 2015. AMG’s European businesses were sold to RTL Group and Atres Media in 2016 and 2017. PROFILE - WELLINGTON PARTNERS Venture Capital for life science. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. CONTACT - WELLINGTON PARTNERS Toggle navigation. Wellington Partners. Home; Team; Approach; Portfolio; News; Contact Munich. Türkenstraße 5; 80333 Munich; Germany +49 (0) 89 21 99 41 0 PROFILE - WELLINGTON PARTNERS Biography. Johannes joined Wellington Partners in 2020 as a Senior Associate in the Life Sciences Team. Johannes gained a Bachelor and a Master degree in Biochemistry, graduated as a medical doctor and holds a PhD in Biotechnology. PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. NEWS - WELLINGTON PARTNERS Venture Capital for life science. Uromems closes €14m financing to develop its smart artificial urinary sphincter to market PROFILE - WELLINGTON PARTNERS Biography. Dr. Ulrich Granzer joined Wellington in 2004 as a Venture Partner on the Life Science team. He advises on drug development andregulatory affairs.
PROFILE - WELLINGTON PARTNERS Biography. Christian joined Wellington as a General Partner in September 2009. Prior to that Christian spent nine years with Apax Partners – where he was a Partner in the Tech & Telecom team. WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PORTFOLIO - WELLINGTON PARTNERS Polares Medical was created as a spin-off of Symetis. Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic. Rigontec was acquired by Merck & Co. in 2017 for up to US$553M. Sapiens was acquired by Medtronic in 2014 for US$200M.HOME
For twenty years Wellington Partners Technology has been a leading European Venture Capital firm focussing on investments in early- and growth-stage technology companies. The Wellington Partners Technology Team has raised and invested five generations of Venture Capital funds. In total we have invested € 640 million in 120 companiesacross
PORTFOLIO - WELLINGTON PARTNERS ACG went public on the German Stock Exchange in 1999. The company was acquired by Assa Abloy in 2003. Location: Germany. Activity: Identification Technology. Wellington contact: Frank Böhnke. Go to website. Adconion Media Group (AMG) AMG’s US was sold to Amobee Inc. for $235 million in 2015. AMG’s European businesses were sold to RTLGroup
TEAM - WELLINGTON PARTNERS Christian Reitberger General Partner Show Profile. Harald Keller CFO Show Profile. Ernst Mannheimer Legal Counsel Show Profile PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PROFILE - WELLINGTON PARTNERS Ernst Mannheimer. General Partner, Legal Counsel. Diligence is the mother of good luck. — Benjamin Franklin. Biography. Ernst Mannheimer joined Wellington in 1993 after one year as assistant to the CEO of the Matuschka Group, the investment banking, venture capital, real estate and M&A organization co-founded by Rolf ChristofDienst.
PROFILE - WELLINGTON PARTNERS In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases. He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology andimmunology.
PROFILE - WELLINGTON PARTNERS Biography. Harald Keller joined Wellington in 1998. He focuses on fund management, fund structures, finance & reporting, investor relations and information technology. He also co-heads Swiss-based Wellington Partners Advisory AG. Harald began his career in 1990 as a finance manager at Procter & Gamble in Schwalbach, Germany, where he spentfour
PROFILE - WELLINGTON PARTNERS Biography. Christian joined Wellington as a General Partner in September 2009. Prior to that Christian spent nine years with Apax Partners – where he was a Partner in the Tech & Telecom team. Before, Christian worked with McKinsey. Christian earned a PhD in physics from the University of Vienna with sub auspiciis praesidentisdistinction.
PROFILE - WELLINGTON PARTNERS Dr. Ulrich Granzer has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002, providing regulatory advice to more than 500 Life Science companies. He has an in-depth overview over current drug development programs as well as detailed insight into the requirements of major regulatoryagencies.
WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS Ernst Mannheimer. General Partner, Legal Counsel. Diligence is the mother of good luck. — Benjamin Franklin. Biography. Ernst Mannheimer joined Wellington in 1993 after one year as assistant to the CEO of the Matuschka Group, the investment banking, venture capital, real estate and M&A organization co-founded by Rolf ChristofDienst.
WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS Ernst Mannheimer. General Partner, Legal Counsel. Diligence is the mother of good luck. — Benjamin Franklin. Biography. Ernst Mannheimer joined Wellington in 1993 after one year as assistant to the CEO of the Matuschka Group, the investment banking, venture capital, real estate and M&A organization co-founded by Rolf ChristofDienst.
HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture Partners NEWS - WELLINGTON PARTNERS Venture Capital for life science. Uromems closes €14m financing to develop its smart artificial urinary sphincter to market PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
NEWS - WELLINGTON PARTNERS 4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208. NEWS - WELLINGTON-PARTNERS.COM The Supervisory Board of AYOXXA announces that following his initial assumption of the duties of CEO in October, Rodney Turner will continue to lead the company on a permanent basis NEWS - WELLINGTON PARTNERS Austrian biotech company Themis Bioscience said it had started a clinical trial of an experimental Zika vaccine in healthy volunteers. PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Johannes joined Wellington Partners in 2020 as a Senior Associate in the Life Sciences Team. Johannes gained a Bachelor and a Master degree in Biochemistry, graduated as a medical doctor and holds a PhD in Biotechnology. In his PhD research at King Abdullah University of Science and Technology and Technical University Munich, Johannesexplored
NEWS - WELLINGTON PARTNERS News. Symetis acquires Middle Peak Medical. Details. Published: 14 February 2017. wellington-news. Symetis has announced the acquisition of Middle Peak Medical. Wellington Partners led the Series A investment into Middle Peak in 2013. 4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup. Details. PROFILE - WELLINGTON PARTNERS Biography. Christian joined Wellington as a General Partner in September 2009. Prior to that Christian spent nine years with Apax Partners – where he was a Partner in the Tech & Telecom team. Before, Christian worked with McKinsey. Christian earned a PhD in physics from the University of Vienna with sub auspiciis praesidentisdistinction.
WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERSWELLINGTON PARTNERS COLLECTIONSWELLINGTON PARTNERS INSURANCEWELLINGTON PARTNERS MUNICHWELLINGTON PARTNERS YACHTS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases. He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology andimmunology.
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERSWELLINGTON PARTNERS COLLECTIONSWELLINGTON PARTNERS INSURANCEWELLINGTON PARTNERS MUNICHWELLINGTON PARTNERS YACHTS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases. He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology andimmunology.
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PORTFOLIO - WELLINGTON PARTNERS Polares Medical was created as a spin-off of Symetis. Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic. Rigontec was acquired by Merck & Co. in 2017 for up to US$553M. Sapiens was acquired by Medtronic in 2014 for US$200M. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
NEWS - WELLINGTON PARTNERS Venture Capital for life science. Uromems closes €14m financing to develop its smart artificial urinary sphincter to market PROFILE - WELLINGTON PARTNERS Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PROFILE - WELLINGTON PARTNERS Ernst Mannheimer. General Partner, Legal Counsel. Diligence is the mother of good luck. — Benjamin Franklin. Biography. Ernst Mannheimer joined Wellington in 1993 after one year as assistant to the CEO of the Matuschka Group, the investment banking, venture capital, real estate and M&A organization co-founded by Rolf ChristofDienst.
PROFILE - WELLINGTON PARTNERS Biography. Arturo joined Wellington Partners as an Associate in 2019 and was promoted to Senior Associate in 2020. Prior to joining Wellington, Arturo worked as an Investment Analyst at the Life Science Team of M Ventures in the Netherlands, where he was involved in several investment processes including Riffyn, DNA Script, Plexium and Pantheon Biosciences. NEWS - WELLINGTON PARTNERS 4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208. PROFILE - WELLINGTON PARTNERS Biography. Marianne joined Wellington Partners in 2018 as a Principal in the Life Science Team. Marianne obtained a Bachelor’s and Master’s degree with distinction in Biotechnology from the RWTH Aachen University, Germany, and The Scripps Research Institute, San Diego, USA, and conducted her PhD research in the field of Molecular Imaging at the Helmholtz-Institute for Biomedical PROFILE - WELLINGTON PARTNERS Dr. Ulrich Granzer has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002, providing regulatory advice to more than 500 Life Science companies. He has an in-depth overview over current drug development programs as well as detailed insight into the requirements of major regulatoryagencies.
PROFILE - WELLINGTON PARTNERS Biography. Christian joined Wellington as a General Partner in September 2009. Prior to that Christian spent nine years with Apax Partners – where he was a Partner in the Tech & Telecom team. Before, Christian worked with McKinsey. Christian earned a PhD in physics from the University of Vienna with sub auspiciis praesidentisdistinction.
WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERSWELLINGTON PARTNERS COLLECTIONSWELLINGTON PARTNERS INSURANCEWELLINGTON PARTNERS MUNICHWELLINGTON PARTNERS YACHTS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases. He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology andimmunology.
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently WELLINGTON PARTNERS VENTURE CAPITALTECHNOLOGYLIFE SCIENCES Think bigger. Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors: Technology › Life Sciences ›.HOME
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response. More news. #ThinkBigger. TEAM - WELLINGTON PARTNERSWELLINGTON PARTNERS COLLECTIONSWELLINGTON PARTNERS INSURANCEWELLINGTON PARTNERS MUNICHWELLINGTON PARTNERS YACHTS Ernst Mannheimer General Partner, Legal Counsel Show Profile. Rolf Christof Dienst Partner emeritus Show Profile. Venture PartnersSFDR DISCLOSURES
SFDR Disclosures Transparency of sustainability risk policies (SFDR Art. 3) Commitment to ESG Wellington Partners is convinced that responsible investment creates a closer alignment of objectives among investors, investee companies and society at large and will lead to enhanced and more sustainable financial returns in the long run. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
PROFILE - WELLINGTON PARTNERS Biography. Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma, ONWARD, Sidekick, SNIPR Biome and STipe. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / BostonScientific
PROFILE - WELLINGTON PARTNERS Biography. Dr. Wolfgang Baiker is CEO at WPLS-V portfolio company Adrenomed AG, Hennigsdorf/Berlin (Germany), which he joined in October 2020. Previously, he spent more than 30 years at Boehringer Ingelheim, Ingelheim (Germany), the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. Inhis
PROFILE - WELLINGTON PARTNERS Previously, Karl was a Partner at Gimv, a publicly listed private equity and venture capital investment firm, where he had been responsible for life science investments within Gimv’s Health & Care team, since 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-basedventure
PROFILE - WELLINGTON PARTNERS In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases. He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology andimmunology.
PROFILE - WELLINGTON PARTNERS VENTURE CAPITAL Dr. Bo Jesper Hansen. Venture Partner. Biography. Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently PORTFOLIO - WELLINGTON PARTNERS Polares Medical was created as a spin-off of Symetis. Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic. Rigontec was acquired by Merck & Co. in 2017 for up to US$553M. Sapiens was acquired by Medtronic in 2014 for US$200M. PROFILE - WELLINGTON PARTNERS Partner emeritus. LinkedIn. Biography. Wellington Partners founder Rolf Christof Dienst has been a leading entrepreneur in the VC industry and Life Sciences sector for over 30 years, playing a key role in shaping the German VC landscape. At Wellington some of his investments include healthcare specialists PST, MediMedia andMedigene, a biotech
NEWS - WELLINGTON PARTNERS Venture Capital for life science. Uromems closes €14m financing to develop its smart artificial urinary sphincter to market PROFILE - WELLINGTON PARTNERS Biography. With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech,medtech
PROFILE - WELLINGTON PARTNERS Ernst Mannheimer. General Partner, Legal Counsel. Diligence is the mother of good luck. — Benjamin Franklin. Biography. Ernst Mannheimer joined Wellington in 1993 after one year as assistant to the CEO of the Matuschka Group, the investment banking, venture capital, real estate and M&A organization co-founded by Rolf ChristofDienst.
PROFILE - WELLINGTON PARTNERS Biography. Arturo joined Wellington Partners as an Associate in 2019 and was promoted to Senior Associate in 2020. Prior to joining Wellington, Arturo worked as an Investment Analyst at the Life Science Team of M Ventures in the Netherlands, where he was involved in several investment processes including Riffyn, DNA Script, Plexium and Pantheon Biosciences. NEWS - WELLINGTON PARTNERS 4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208. PROFILE - WELLINGTON PARTNERS Biography. Marianne joined Wellington Partners in 2018 as a Principal in the Life Science Team. Marianne obtained a Bachelor’s and Master’s degree with distinction in Biotechnology from the RWTH Aachen University, Germany, and The Scripps Research Institute, San Diego, USA, and conducted her PhD research in the field of Molecular Imaging at the Helmholtz-Institute for Biomedical PROFILE - WELLINGTON PARTNERS Dr. Ulrich Granzer has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002, providing regulatory advice to more than 500 Life Science companies. He has an in-depth overview over current drug development programs as well as detailed insight into the requirements of major regulatoryagencies.
PROFILE - WELLINGTON PARTNERS Biography. Christian joined Wellington as a General Partner in September 2009. Prior to that Christian spent nine years with Apax Partners – where he was a Partner in the Tech & Telecom team. Before, Christian worked with McKinsey. Christian earned a PhD in physics from the University of Vienna with sub auspiciis praesidentisdistinction.
THINK BIGGER
Since the 1990s we have been delighted to support the global ambitions of Europe's best entrepreneurs and to help them become global leaders in their businesses. We work with the best in two dedicated sectors:Technology ›
Life Sciences › © 2020 Wellington Partners | Terms and ConditionsDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0